Regavirumab is a monoclonal antibody that has been primarily investigated for its antiviral properties, particularly against certain viral infections. As a therapeutic agent, it functions by targeting specific viral proteins, thereby inhibiting the virus's ability to replicate and spread within the host. Regavirumab is characterized by its high specificity and affinity for its target, which is a common feature of monoclonal antibodies. This specificity allows for reduced off-target effects compared to traditional antiviral medications. The substance is typically administered via injection and may be used in various clinical settings, depending on the viral infection being treated. Its development is part of a broader trend in medicine towards targeted therapies that leverage the immune system to combat infections. As with many monoclonal antibodies, potential side effects may include allergic reactions or infusion-related reactions, and its use is often accompanied by careful monitoring in clinical settings. Overall, Regavirumab represents a significant advancement in the field of antiviral therapeutics.

Regavirumab

153101-26-9: Regavirumab is a monoclonal antibody that has been primarily investigated for its antiviral properties, particularly against certain viral infections. As a therapeutic agent, it functions by targeting specific viral proteins, thereby inhibiting the virus's ability to replicate and spread within the host. Regavirumab is characterized by its high specificity and affinity for its target, which is a common feature of monoclonal antibodies. This specificity allows for reduced off-target effects compared to traditional antiviral medications. The substance is typically administered via injection and may be used in various clinical settings, depending on the viral infection being treated. Its development is part of a broader trend in medicine towards targeted therapies that leverage the immune system to combat infections. As with many monoclonal antibodies, potential side effects may include allergic reactions or infusion-related reactions, and its use is often accompanied by careful monitoring in clinical settings. Overall, Regavirumab represents a significant advancement in the field of antiviral therapeutics.

<p>Regavirumab (MCA C23), a human monoclonal antibody, targets cytomegalovirus (CMV), human serum albumin (HSA), and amino acetic acid [1].</p>

<p>Anti-cytomegalovirus glycoprotein B human monoclonal antibody</p>

CAS 153101-26-9

Regavirumab

Regavirumab

Ref: TM-T77146

Regavirumab

Ref: 3D-CLA1161